XML 72 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Acquisitions - Narrative (Details)
€ in Millions
1 Months Ended 12 Months Ended
Mar. 04, 2021
USD ($)
Mar. 04, 2021
EUR (€)
Oct. 23, 2020
USD ($)
Apr. 07, 2020
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Apr. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Mar. 04, 2021
EUR (€)
Business Acquisition [Line Items]                      
Discount rate of acquired IPR&D           6.50% 8.00% 9.50%      
Acquired in-process research and development expenses           $ 177,000,000 $ 5,856,000,000 $ 4,251,000,000      
Acquired IPR&D                      
Business Acquisition [Line Items]                      
Reclassified intangible assets                 $ (1,000,000,000) $ (910,000,000)  
Trodelvy                      
Business Acquisition [Line Items]                      
Reclassified intangible assets                 $ 1,000,000,000    
Forty Seven, Inc.                      
Business Acquisition [Line Items]                      
Accelerated stock-based expense             144,000,000        
Total consideration, net of acquired cash       $ 4,700,000,000              
Forty Seven, Inc. | Acquired IPR&D                      
Business Acquisition [Line Items]                      
Acquired in-process research and development expenses             4,500,000,000        
MYR                      
Business Acquisition [Line Items]                      
Consideration $ 1,600,000,000 € 1,300                  
Cash payments made for acquisition 1,200,000,000 € 1,000                  
Goodwill 226,000,000                    
Goodwill expected to be deductible for tax purposes           0          
MYR | Level 3 | Fair value, recurring                      
Business Acquisition [Line Items]                      
Liability for MYR GmbH (“MYR”) contingent consideration 341,000,000         317,000,000 0        
MYR | Maximum                      
Business Acquisition [Line Items]                      
Liability for MYR GmbH (“MYR”) contingent consideration | €                     € 300
MYR | Acquired IPR&D                      
Business Acquisition [Line Items]                      
Aggregate fair value of acquired IPR&D 1,190,000,000                    
MYR | Hepcludex                      
Business Acquisition [Line Items]                      
Aggregate fair value of acquired IPR&D $ 1,190,000,000                    
MYR | Hepcludex | Measurement Input, Discount Rate                      
Business Acquisition [Line Items]                      
Discount rate of acquired IPR&D 12.00%                   12.00%
MYR | Hepcludex                      
Business Acquisition [Line Items]                      
Finite-lived intangible asset $ 845,000,000                    
Estimated useful life of finite-lived intangible asset acquired 10 years 10 years                  
MYR | Hepcludex | Measurement Input, Discount Rate                      
Business Acquisition [Line Items]                      
Discount rate of finite-lived intangible asset acquired 12.00%                   12.00%
Immunomedics, Inc.                      
Business Acquisition [Line Items]                      
Consideration     $ 20,600,000,000                
Goodwill     3,991,000,000                
Goodwill expected to be deductible for tax purposes     0                
Accelerated stock-based expense             289,000,000        
Acquisition-related expenses             39,000,000        
Fair value step-up adjustment of inventories acquired     881,000,000                
Inventories     946,000,000     $ 294,000,000 $ 797,000,000        
Liability related to future royalties     $ 1,100,000,000                
Immunomedics, Inc. | Measurement Input, Risk Free Interest Rate                      
Business Acquisition [Line Items]                      
Liability related to future royalties, measurement Input     0.025                
Immunomedics, Inc. | Measurement Input, Expected Term                      
Business Acquisition [Line Items]                      
Liability related to future royalties, measurement Input     16                
Immunomedics, Inc. | Three year senior unsecured term loan facility | Medium-term notes                      
Business Acquisition [Line Items]                      
Borrowing under the senior unsecured term loan facility         $ 1,000,000,000            
Immunomedics, Inc. | Acquired IPR&D                      
Business Acquisition [Line Items]                      
Aggregate fair value of acquired IPR&D     $ 15,760,000,000                
Discount rate of acquired IPR&D     7.00%                
Immunomedics, Inc. | Trodelvy                      
Business Acquisition [Line Items]                      
Finite-lived intangible asset     $ 4,600,000,000                
Discount rate of finite-lived intangible asset acquired     7.00%                
Estimated useful life of finite-lived intangible asset acquired     12 years                
Immunomedics, Inc. | Outlicense contract                      
Business Acquisition [Line Items]                      
Finite-lived intangible asset     $ 175,000,000                
Discount rate of finite-lived intangible asset acquired     7.00%                
Estimated useful life of finite-lived intangible asset acquired     15 years